Johnson & Johnson will remain the name of the business behind treatments such as Darzalex, Stelara and Tremfya, medical devices and the COVID-19 vaccine, according to The Associated Press and CNBC.
“For the new Johnson & Johnson, this planned separation underscores our focus on delivering industry-leading biopharmaceutical and medical device innovation and technology with the goal of bringing new solutions to market for patients and healthcare systems, while creating sustainable value for shareholders,” Alex Gorsky, Johnson & Johnson’s CEO, said in the release.
By using this website, you accept the terms of our Visitor Agreement and Privacy Policy, and understand your options regarding Ad Choices.